(Q36577391)

15 August 2017

1 reference

title

B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

15 August 2017

1 reference

0 references

author name string

Robert Eisenberg

series ordinal

1

1 reference

15 August 2017

Daniel Albert

series ordinal

2

1 reference

15 August 2017

publication date

1 January 2006

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

20-27

1 reference

Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

B cell targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Defective B cell tolerance checkpoints in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Impaired early B cell tolerance in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Common variable immunodeficiency in a patient with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

The role of B cell abnormalities in the systemic autoimmune syndromes of lpr and gld mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

CD20: a regulator of cell-cycle progression of B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Mice carrying a CD20 gene disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Efficacy and safety of rituximab in type II mixed cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

B cell depletion therapy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Costimulation requirements of induced murine systemic autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Rationale for interleukin-6 blockade in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

The role of interleukin-10 in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Fas-induced apoptosis in B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Dendritic cells control B cell growth and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Regulatory roles for cytokine-producing B cells in infection and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Toll-like receptors as potential therapeutic targets for multiple diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Heterogeneity of immunoglobulin-associated molecules on human B cells identified by monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Homing of antibody secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Positioning the immune system: unexpected roles for alpha6-integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Prospects for B-cell-targeted therapy in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Treatment of childhood autoimmune haemolytic anaemia with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

The biology of CD20 and its potential as a target for mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

CD20-mediated apoptosis: signalling through lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

Do autoantigens define autoimmunity or vice versa?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

T cell activation in rheumatoid synovium is B cell dependent

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

Restoration of tolerance in lupus by targeted inhibitory receptor expression

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

B lymphocyte depletion in rheumatoid arthritis: targeting of CD20

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

Natalizumab and progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab)

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0042

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0042

1 reference

15 August 2017

1 reference